<DOC>
	<DOCNO>NCT01117181</DOCNO>
	<brief_summary>The Apathy Dementia Methylphenidate Trial ( ADMET ) mask , placebo-controlled trial examine efficacy safety methylphenidate treatment clinically significant apathy patient Alzheimer 's dementia .</brief_summary>
	<brief_title>Apathy Dementia Methylphenidate Trial ( ADMET )</brief_title>
	<detailed_description>The Apathy Dementia Methylphenidate Trial ( ADMET ) , fund National Institute Aging , Phase II , placebo-controlled , masked , 3-center randomized clinical trial . ADMET enroll 60 patient Alzheimer 's disease ( AD ) significant apathy outpatient , nursing home , assist living facility along primary caregiver . Eligible willing patient randomly assign methylphenidate ( 20 mg per day ) placebo . At baseline in-person follow-up visit , caregiver patient provide standardized psychosocial intervention consist counsel session , provision educational material , 24-hour availability crisis . Efficacy safety outcome measure baseline in-person follow-up visit 2 , 4 , 6 week follow randomization . Telephone contact take place 1 , 3 , 5 week randomization . ADMET 80 % power detect difference least 3.3 change Apathy Evaluation Scale score two treatment group . It also 80 % power detect absolute difference 35 % change proportion study participant improve te Clinical Global Impression Change , give 20 % 305 participant placebo group show improvement .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Inclusion criterion : Possible probable Alzheimer 's disease ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion ) , MiniMental State Exam ( MMSE ) score 1026 inclusive ; MMSE score 26 nevertheless meet criterion AD may allow Steering Committee approval case case basis Clinically significant apathy least four week either 1 ) frequency apathy assess Neuropsychiatric Inventory ( NPI ) 'Very frequently ' , 2 ) frequency apathy assess NPI 'Frequently ' 'Often ' AND severity apathy assess NPI 'Moderate ' 'Marked ' A medication apathy appropriate , opinion study physician Provision inform consent participation study patient surrogate ( patient unable provide inform consent ) caregiver Availability primary caregiver , spend great ten hour week patient supervise his/her care , accompany patient study visit participate study Sufficient fluency , patient caregiver , write spoken English participate study visit , physical exam , outcome assessment No change AD medication within month precede randomization , include start , stop , dosage modification Treatment stable dos selective serotonin reuptake inhibitor antidepressant ( SSRIs ) appropriate stable 3 month prior randomization . Other psychotropics ( exclusion antipsychotic ) , stable 3 month , may allow Steering Committee approval case case basis . Exclusion criterion : Meets criteria Major Depressive Episode , Diagnostic Statistical Manual Mental Disorder IV ( TR ) criteria Clinically significant agitation /aggression either 1 ) frequency agitation /aggression assess NPI 'Very frequently ' , 2 ) frequency agitation /aggression assess NPI 'Frequently ' AND severity agitation assess NPI 'Moderate ' , 'Marked ' Clinically significant delusion either 1 ) frequency delusion assess NPI 'Very frequently ' , 2 ) frequency delusion assess NPI 'Frequently ' AND severity delusion assess NPI 'Moderate ' , 'Marked ' Clinically significant hallucination either 1 ) frequency hallucination assess NPI 'Very frequently ' , 2 ) frequency hallucination assess NPI 'Frequently ' AND severity hallucination assess NPI 'Moderate ' , 'Marked ' Treatment psychotropic medication 2 week prior randomization exception approve treatment dementia ( ChEIs memantine ) , selective serotonin reuptake inhibitor antidepressant , trazodone ( use aid facilitate sleep antidepressant ) ; psychotropics ( exclusion antipsychotic ) , stable 3 month , may allow Steering Committee approval case case basis . Note antipsychotics expressly prohibit . Treatment methylphenidate contraindicate opinion study physician Failure treatment methylphenidate past apathy convince evidence adequate trial judge study physician Treatment medication would prohibit safe concurrent use methylphenidate monoamine oxidase inhibitor tricyclic antidepressant Need acute psychiatric hospitalization suicidal Uncontrolled hypertension ( medication noncompliance past 3 month diastolic read 105 verified compartment pressure rectus sheath ( CPRS ) ) Symptomatic coronary artery disease deem significant study physician time screen Lack appetite result significant unintentional weight loss determine study physician last three month Significant communicative impairment Current participation clinical trial study may add significant burden affect study outcomes Hyperthyroidism , advance arteriosclerosis , symptomatic cardiovascular disease , serious structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , family history sudden death death related heart problem Glaucoma , pheochromocytoma , know suspected hypersensitivity methylphenidate excipients Central Nervous System ( CNS ) abnormality ( e.g. , cerebral aneurysm ) and/or vascular abnormality vasculitis preexist stroke , motor tic family history diagnosis Tourette 's syndrome , seizure ( convulsion , epilepsy ) , abnormal EEGs Any condition , opinion study physician , make medically inappropriate risky patient enroll trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Dopaminergic agent</keyword>
	<keyword>Apathy Evaluation Scale</keyword>
	<keyword>Dementia</keyword>
</DOC>